This website is intended for healthcare professionals only.

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Share this article

Follow by Email
Facebook
Twitter

Study investigates outcomes of COVID infection in liver transplant patients


8 September, 2020  

Although liver transplant patients are prescribed immunosuppressant therapy, this not appear to increase their susceptibility to mortality when hospitalised due to COVID-19.

This is the conclusion of a new analysis by an international team of researchers, of data contained in two disease registries, COVID-Hep (based in the UK) and SECURE-Cirrhosis (based in the US).

For the study, the team collected information on 151 recipients from 18 countries, with a median age of 60 years (32% women) and compared the outcomes with a control group of 627 (median age 73 years, 48% women) non-transplant patients. The major outcome of interest was death although the researchers also examined rates of intensive care admission. A similar number of patients were hospitalised (82% vs 76%, transplant vs control group) although a higher proportion of transplant patients were admitted to intensive care (28% vs 8%, p < 0.0001) and given intensive ventilation (20% vs 5%, p < 0.0001).

However, the proportion of patients dying was lower in the transplant group (19% vs 27%, p = 0.046) and none of the deaths were liver-related. Further analysis revealed that age, serum creatinine levels and non-liver cancer were associated with an increased risk of death among transplant patients.

The authors concluded factors such as age and co-morbidities were more important predictors of mortality than transplantation.

Reference
Webb GJ et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol 2020; August 28: https://doi.org/10.1016/ S2468-1253(20)30271-5